EPRX
Eupraxia Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · CA
$8.40
+12.00%Aug 13, 2026, 12:00 UTC
Eupraxia Pharmaceuticals reported positive symptom response data from its ongoing Phase 1b/2a RESOLVE trial for EP-104GI in eosinophilic esophagitis patients, showing reductions in odynophagia and dysphagia severity through 52 weeks post treatment.
Source:Aug 11, 2026, 21:21 UTC
Eupraxia Pharmaceuticals presented new data at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI.
Source:Jul 7, 2026, 12:00 UTC
Eupraxia Pharmaceuticals appointed Robert Bazemore, Amy Pott, and Dr. Helen Thackray to its Board of Directors.
Source: